Innoviva Share Price Today
(NASDAQ: INVA)

Name: Innoviva Share Price Today (NASDAQ: INVA) - Innoviva Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Innoviva share price is $18.05 & ₹1,542.51 as on 26 Apr 2025, 2.30 'hrs' IST

$18.05

▲

-0.33

(-1.8%)

Live

View live Innoviva share price in Dollar and Rupees. Guide to invest in Innoviva stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Innoviva, along with analyst recommendations, forecasts, and comprehensive financials.

Innoviva share price movements

Today's Low: $18.01
Today's High: $18.32
$18.05
0.22%
Downside
Day's Volatility :1.69%
Upside
1.47%
52 Weeks Low: $14.90
52 Weeks High: $21.28
$18.05
17.48%
Downside
52 Weeks Volatility :30.0%
Upside
15.18%

Innoviva (INVA) Returns

Period	Innoviva, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.71%	-4.8%	0.0%
6 Months	-7.03%	-7.5%	0.0%
1 Year	22.62%	-1.8%	0.0%
3 Years	6.8%	2.1%	-9.5%

Innoviva (INVA) Key Statistics

in dollars & INR

Previous Close	$18.38
Open	$18.32
Today's High	$18.32
Today's Low	$18.01
Market Capitalization	$1.2B
Today's Volume	$551.9K
52 Week High	$21.28
52 Week Low	$14.895
Revenue TTM	$358.7M
EBITDA	$206.7M
Earnings Per Share (EPS)	$0.36
PE Ratio	51.06
Profit Margin	6.52%
Quarterly Earnings Growth YOY	-0.63%
Return On Equity TTM	3.43%

How to invest in Innoviva Stock (INVA) from India?

It is very easy for Indian residents to invest directly in Innoviva from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Innoviva stock in both Indian Rupees (INR) and US Dollars (USD). Search for Innoviva or INVA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Innoviva or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Innoviva shares which would translate to 0.047 fractional shares of Innoviva as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Innoviva, in just a few clicks!

Returns in Innoviva (INVA) for Indian investors in Rupees

The Innoviva stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Innoviva investment value today

Current value as on today

₹1,22,989

Returns

₹22,989

(+22.99%)

Returns from Innoviva Stock

₹20,414 (+20.41%)

Dollar Returns

₹2,575 (+2.58%)

Indian investors sentiment towards Innoviva (INVA)

17%

Period: Mar 25, 2025 to Apr 24, 2025. Change in 30 Days versus previous period

Search interest for Innoviva Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Innoviva

BlackRock Inc
15.17%
Sarissa Capital Management LP
11.59%
Vanguard Group Inc
10.06%
Dimensional Fund Advisors, Inc.
7.84%
Franklin Resources Inc
7.06%
Renaissance Technologies Corp
6.79%

Analyst Recommendation on Innoviva

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Innoviva(by analysts ranked 0 to 5 stars)

Analyst Forecast on Innoviva Stock (INVA)

What analysts predicted

Upside of 5.26%

Target:

$19.00

Current:

$18.05

Insights on Innoviva Stock (Ticker Symbol: INVA)

Price Movement
In the last 1 month, INVA stock has moved up by 5.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 89.50M → 91.80M (in $), with an average increase of 2.5% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -34.68M → 20.33M (in $), with an average increase of 1526.7% per quarter
INVA vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 72.4% return, outperforming this stock by 49.8%
INVA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.3% return, outperforming this stock by 54.0%
Price to Sales
ForINVA every $1 of sales, investors are willing to pay $3.2, whereas for Beone Medicines Ltd, the investors are paying $7.1 for every $1 of sales.

Innoviva Technicals Summary

Sell

Neutral

Buy

Innoviva is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Innoviva (INVA) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Innoviva, Inc.	5.51%	-7.03%	22.62%	6.8%	38.2%
Regeneron Pharmaceuticals, Inc.	-6.31%	-35.72%	-32.66%	-11.12%	9.54%
Beone Medicines Ltd	2.09%	20.37%	72.43%	67.9%	55.25%
Vertex Pharmaceuticals Incorporated	-1.56%	3.09%	23.83%	83.97%	83.41%
Alnylam Pharmaceuticals, Inc.	-9.88%	-14.83%	68.82%	56.52%	70.01%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Innoviva, Inc.	51.06	51.06	0.24	0.0	0.03	0.09	NA	11.03
Regeneron Pharmaceuticals, Inc.	15.27	15.27	0.94	39.99	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Innoviva, Inc.	Sell	$1.2B	38.2%	51.06	6.52%
Regeneron Pharmaceuticals, Inc.	Buy	$64.0B	9.54%	15.27	31.07%
Beone Medicines Ltd	NA	$28.7B	55.25%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.6B	83.41%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.3B	70.01%	NA	-12.37%

About Innoviva

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Organization	Innoviva
Employees	127
CEO	Mr. Pavel Raifeld C.F.A.
Industry	Health Technology

Management People of Innoviva

Name	Title
Mr. Pavel Raifeld C.F.A.	CEO & Director
Mr. Stephen Basso M.B.A.	Chief Financial Officer
Ms. Marianne Zhen CPA	Chief Accounting Officer & Secretary
Ms. Patricia M. Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.

Important FAQs about investing in INVA Stock from India :

What is Innoviva share price today?

Innoviva share price today stands at $18.05, Open: $18.37 ; Previous Close: $18.38 ; High: $18.32 ; Low: $18.01 ; 52 Week High: $21.28 ; 52 Week Low: $14.90.

The stock opens at $18.37, after a previous close of $18.38. The stock reached a daily high of $18.32 and a low of $18.01, with a 52-week high of $21.28 and a 52-week low of $14.90.

Can Indians buy Innoviva shares?

Yes, Indians can invest in the Innoviva (INVA) from India.

With INDmoney, you can buy Innoviva at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Innoviva at zero transaction cost.

How can I buy Innoviva shares from India?

It is very easy to buy Innoviva from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Innoviva (INVA) be purchased?

Yes, you can buy fractional shares of Innoviva with INDmoney app.

What are the documents required to start investing in Innoviva stocks?

To start investing in Innoviva, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.